321 HARRISON AVENUE, BOSTON, MA
Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Amended material disclosure
Annual Report to Security Holders
Investor Presentation
Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
Provides Business Update and Reports Third Quarter 2025 Financial Results
Reports Second Quarter 2025 Financial Results and Provides Business Update
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 424(b)(2)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership